# Claim table — COVID hospital-protocol / profit Reel

| Claim | Evidence label | Source-check note |
|---|---|---|
| A critical-care nurse, Kimberly Overton, made the allegation on Jimmy Dore’s show. | Supported as a public claim. | Instagram metadata, frame capture and podcast mirrors identify the segment and claims. |
| U.S. Medicare paid more for inpatient COVID cases during the public-health emergency. | Supported. | CMS SE20015 says the CARES Act increased the MS-DRG weighting factor by 20% for COVID-19 inpatient discharges during the PHE, with positive-test documentation required for admissions on/after Sept. 1, 2020. |
| Medicare had a new-treatment add-on payment that included remdesivir/VEKLURY in eligible cases. | Supported with limits. | CMS says NCTAP was designed to mitigate financial disincentives for new COVID treatments, including VEKLURY, and ended Sept. 30, 2023. |
| Those payment rules prove hospitals killed patients on purpose for profit. | Not established. | Payment incentives and billing risks are real audit topics, but they do not by themselves prove intent to kill. HHS OIG’s 2023 COVID inpatient-payment audit found 146/149 sampled claims compliant and $18,911 in improper payments, mainly clerical errors. |
| Ventilated COVID patients had very high mortality. | Supported, with range/context. | Severe COVID requiring invasive ventilation had high reported mortality. Later reviews commonly report around 40–50%; early 80–88% headlines relied on incomplete outcome/censoring problems. |
| Ventilators themselves killed most patients. | Not proven as stated. | Mechanical ventilation is a life-support intervention for severe respiratory failure/ARDS. It carries risk and can be overused/mis-timed, but high mortality also reflects severe disease and patient risk. |
| Remdesivir was weak or not useful once patients were mechanically ventilated. | Partly supported. | Evidence and guidelines are less favorable for routine initiation in already mechanically ventilated patients; benefit appears clearer earlier/noncritically ill patients needing oxygen. |
| Remdesivir was simply a poison/profit drug that caused COVID deaths. | Overstated/unproven. | Trials/meta-analyses are mixed by disease stage. Concerns about kidney/liver monitoring and late-stage use do not prove deliberate killing. |
| High-dose fentanyl/propofol/midazolam guaranteed patients could not be weaned. | Not established as a general claim. | Deep sedation can be clinically needed in severe ARDS and can delay liberation if excessive. Guidelines emphasize avoiding oversedation and using daily breaks when safe. |
| Doctors/journalists self-policed and dissenters were discredited. | Interpretation / debate. | The Reel’s broader institutional-incentive argument is political/media commentary, not a single falsifiable medical fact. |

## Bottom line

There are real records behind parts of the concern: COVID add-on payments existed, remdesivir evidence depends heavily on disease stage, and ICU ventilation/sedation decisions during early COVID were difficult and high-stakes. The viral headline “hospitals killed COVID patients on purpose for profit” is not established by the records gathered here.